Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
containing: carbidopa, levodopa, entacapone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) | DRUG | - |
Inclusion Criteria: * Aged 30 to 80 years, inclusive, at time of Parkinson's disease diagnosis * Idiopathic Parkinson's disease with at least 2 cardinal signs of disease: resting tremor, bradykinesia or rigidity * Parkinson's disease impairment warranting treatment with a levodopa formulation accor...
Top 12 of 19 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Eli Lilly and Company | LLY | 3 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| AgeX Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
Carbidopa, levodopa, and entacapone is a fixed-dose combination therapy being developed for Parkinson's disease. It combines three small molecules in a single capsule: carbidopa 25 mg, levodopa 100 mg, and entacapone 200 mg. It is designed to deliver levodopa replacement therapy along with agents that support its use in Parkinson's disease patients.
Novartis AG, which trades under the ticker NVS, is the developer of the fixed-dose carbidopa, levodopa, and entacapone combination. The company sponsored the Phase 3 trial evaluating this capsule formulation in Parkinson's disease.
Carbidopa, levodopa, and entacapone is in Phase 3 development. The single registered trial, NCT00134966, is a completed Phase 3 study. The program is investigational and remains in clinical development for Parkinson's disease.
Carbidopa, levodopa, and entacapone was studied in NCT00134966, titled "A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa." This completed Phase 3 trial enrolled 493 participants with Parkinson's disease across the United States, Canada, Czechia, Israel, Italy, Poland, Portugal, and Turkey.
NCT00134966 was a randomized, double-blind, active-controlled Phase 3 trial comparing fixed-dose carbidopa, levodopa, and entacapone against immediate-release carbidopa/levodopa. It enrolled 493 participants with Parkinson's disease, ages 30 years and older, of all sexes, and did not include healthy volunteers. The study is completed.